MacroGenics secures $60M upfront in expanded ZYNYZ royalty deal with Sagard, plus potential $20M milestone.

MacroGenics has expanded its royalty purchase agreement with Sagard Healthcare Partners, receiving a $60 million upfront payment and the potential to earn an additional $20 million based on 2026 sales milestones for ZYNYZ, a cancer treatment drug. The agreement caps Sagard's returns at 1.7x investment by 2032 or 2.0x thereafter, after which royalties revert to MacroGenics. This deal provides MacroGenics with immediate capital while retaining other economic interests in ZYNYZ, which is marketed by Incyte for certain cancers in the US, Europe, and Japan. The expanded agreement supports MacroGenics' ongoing development and commercialization efforts for its antibody-based therapies.